NCT02959047View on ClinicalTrials.gov

A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 17, 2017

Primary Completion Date

May 8, 2023

Study Completion Date

May 8, 2023

Conditions
Peripheral Arterial Disease
Interventions
DRUG

Alirocumab

150mg SQ every 2 weeks

DRUG

Matching placebo

SQ every 2 weeks

Trial Locations (2)

22908

University of Virginia Health System, Charlottesville

60611

Northwestern University, Chicago

All Listed Sponsors
collaborator

Northwestern University

OTHER

lead

University of Virginia

OTHER

NCT02959047 - A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease | Biotech Hunter | Biotech Hunter